• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research

Therapeutics that can shut down harmful genes need a reliable delivery system
(University of Texas at Austin) So far, only a handful of siRNA, or other RNA interference-based therapeutics that can shut down harmful genes to keep viruses from spreading have been approved. Chemical engineering researchers in the Cockrell School of Engineering have created several nanoparticles to help solve the problem of getting the siRNA into the body and guiding it to the target.
Source: EurekAlert! - Medicine and Health - May 17, 2021 Category: International Medicine & Public Health Source Type: news

Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor
Conclusion: These results suggest that EGFR is a potential therapeutic target for MPNST.
Source: Journal of Hematology and Oncology - December 17, 2013 Category: Hematology Authors: Xiaoling DuJilong YangAntti YlipääZe Zhu Source Type: research

New cholesterol drug shows promise
Conclusion Media headlines reporting on this phase I trial concentrated on the secondary outcome (that ALN-PCS reduced LDL cholesterol levels). However, these results will need to be confirmed during phase II and phase III clinical trials, which will involve more participants who would normally receive cholesterol-lowering treatment. While it is tempting to focus on the results of the cholesterol levels, phase I clinical trials are designed to test the safety of a new drug to make sure it is safe enough to test further. They also aim to determine what the highest tolerable dose is, so the appropriate one can be used in la...
Source: NHS News Feed - October 3, 2013 Category: Consumer Health News Tags: Heart/lungs Medical practice Medication Source Type: news